1 / 73

Perioperative Aspirin & POISE-2

Perioperative Aspirin & POISE-2. Neal Gerstein, MD FASE Associate Professor, UNM Department of Anesthesiology Director, UNM Division of Cardiac Anesthesia. Disclosures. None. Objectives. Review risks of holding aspirin perioperatively.

duy
Download Presentation

Perioperative Aspirin & POISE-2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Perioperative Aspirin & POISE-2 Neal Gerstein, MD FASE Associate Professor, UNM Department of Anesthesiology Director, UNM Division of Cardiac Anesthesia

  2. Disclosures • None

  3. Objectives • Review risks of holding aspirin perioperatively. • To learn when / which procedures aspirin should / should not be held. • Review POISE-2 methodology. • Examine limitations of POISE-2. • Provide recommendations on perioperative aspirin management.

  4. Case • 70 y.o. male for primary TKA • PMH • TIA 5 years prior • HTN • NIDDM • HLD • Remote tobacco • Meds • ASA 81 mg/day • Simvastatin • Metformin • Naproxen prn

  5. Background • 100,000,000 non-cardiac operations /year worldwide. • ~ 40% of these patients have / at risk for CV disease. • Mangano, Anesthesiology 1990 • In the U.S., cardiovascular disease (CAD, CVD, PVD): • Affects >1/3 adults • Leading cause of morbidity & mortality. • Wolff et al, Ann Int Med 2009 • USPTF Ann Int Med 2009 • #1 perioperative complication in patients with CV risk factors → M.I. • Associated mortality rate of 15 – 25% • Peter et al, Thromb Haemost 2011 • Kumar et al, J Gen Int Med 2001

  6. Aspirin’s Role in CV Disease • Aspirin • platelet aggregation inhibition • thrombosis prevention • Primary prevention • Secondary prevention • Know aspirin’s indication in these two contexts

  7. Aspirin in Secondary Prevention • Most recent AHA/ACC/ACCP guidelines: • Indefinite rx in virtually all with established CAD or other atherosclerotic disease • ‘unless absolutely contraindicated’ • PCI: neuro, cardiac • 287 study meta-analysis of antiplatelet rx in 135,000 pt’s with CV disease • Aspirin #1 studied rx • 25% reduction of death from any vascular cause, MI, CVA

  8. Primary Prevention • Unclear in those without risk factors • Diabetics • 2010 ADA/AHA/ACCF • Aspirin if increased cardiac risk (10-year risk of cardiac event of >10%). • Men > 50 years / women > 60 years & one of the following: • Tobacco use • Hypertension • Significant cardiovascular disease family history • Hypercholesterolemia • Albuminuria

  9. Aspirin Pharmacology

  10. Key Points in Aspirin Pharmacology • 2 isoforms of COX: 1 & 2 • Aspirin irreversibly inactivates COX • 170x affinity for COX-1 vs COX-2 • A single dose of 30 mg completely suppresses TXA2 production for 1 week

  11. Aspirin Mechanism Eur Heart J, Vol 7, May 2005

  12. Platelets – more than just hemostasis ADP, TXA2 Thrombin coagulation cascade Inflammatory mediators Atherosclerosis Thrombogenicity Neutrophil activation

  13. The ‘Aspirin Withdrawal Syndrome’

  14. ‘Aspirin Withdrawal Syndrome’ • Aspirin use is not just an on-off switch • Complex relationship between platelet: Inhibition Hemostasis Inflammation

  15. Aspirin Withdrawal • Platelet rebound phenomenon in setting of acute aspirin withdrawal. • This rebound period is characterized by: • Increased thromboxane production • Decreased fibrinolysis • Leading to a resultant clinical prothrombotic state • Vial et al, Adv Prostaglandin Thromboxane Leukot Res. 1991 • Beving et al, Blood Coagul Fibrinolysis 1996 • Fatah et al, Eur Heart J 1996

  16. Urine metabolites of TXA2 and PGI2 • Before, during, and after cessation of a 1-week aspirin regimen. • Metabolites (and hence platelet TXA2) rebound to levels beyond that of study controls. • Peaked at 7 to 14 days after aspirin withdrawal.

  17. Measured ‘HHT’ to approximate platelet-TXA2 production • 32 pts who stop aspirin-rx 2 weeks before CABG • 25% of this cohort had 12-HHT levels beyond the normal range2 weeks after withdrawal. • Same investigators, earlier study: • 12-HHT/TXA2 rebound in healthy subjects after withdrawal of a 1-week aspirin regimen. • Dose dependent • more rapid rebound with withdrawal of lower aspirin doses.

  18. Rebound affects more than primary hemostasis • Increase fibrin strength after withdrawal. • Less fibrinolysis when fibrin strength enhanced. • Same authors: • demonstrated that patients with more rigid fibrin networks were more prone to CV events.

  19. Clinically relevant to the Perioperative Period?

  20. Thrombotic Risks of Aspirin Withdrawal in the Perioperative Period • Aspirin is clearly beneficial for secondary prevention. • 25% RRR in preventing future cardiac or ischemic events. • ATC BMJ 2002 • Tran et al, JAMA 2004 • Still, typical practice for surgeons and preoperative clinics to council aspirin cessation 7-10 days preoperatively. • Collet et al, Int J Cardiol 2000

  21. Cohort 1358 pts admitted for ACS. • Non-user: n=930 (68.%) • Prior-users: n=355 (26.1%) • Recent withdrawals: n=73 (5.4%) • 2x increase in death rates of ‘withdrawers’ vs prior users / nonusers. • Average time b/w cessation-cardiac event =11.9 days. • Scheduled surgery = 64% cases. • Multivariate analysis: • Antiplatelet cessation • Independent predictor of both death and major ischemic events.

  22. Meta-analysis of retrospective studies (1970-2004) • n=49590 (14981 on aspirin) • CV risks associated with perioperative withdrawal of aspirin vs bleeding risks when continued.

  23. Withdrawal preceded: • 10.2% of acute cardiovascular events. • 6.1% of lower limb ischemic events. • Mean timing of event after discontinuation of aspirin: • 8.5 days for coronary events. • 25.8 days for a lower limb event.

  24. Retrospective case–control • 309 admissions over 2 years with diagnosis of CVA or TIA & use of long-term aspirin before the index event. • Compared to 309 age- and sex- matched controls with a history of CVA or TIA on long-term aspirin and no acute event in previous 6 months.

  25. CVA/TIA: • 13 patients vs 4 controls had discontinued aspirin in previous 4 weeks: • 4.2% vs 1.3%, P = .03 • Odds ratio 3.34 (95% CI: 1.07–10.39) • Most common reason for aspirin discontinuation: • Surgery • Mean interval between aspirin d/c and CVA: • 9.5 days

  26. Days elapsed between aspirin d/c and thrombotic events: • 10.66 • (95% CI 10.25–11.07) • “… further confirms the major detrimental impact of aspirin withdrawal across a large spectrum of subjects at risk for de-novo or recurrent cardiovascular events.”

  27. Randomized double blind placebo-controlled. • 220 high-risk patients (PCI excluded). • Undergoing intermediate- to high- risk noncardiac surgery. • Randomized to: • daily low-dose aspirin (75mg) or placebo • 7 days before surgery until 3 days post-procedure • Aspirin held if needed in placebo group

  28. Inclusion (one of the following) • CAD • Heart failure • Renal impairment • CVA • TIA • Insulin-dep DM Exclusion • Unstable CAD • Decompensated HF • Shock • Aspirin allergy • < 18 yo • History of ICH, GIB • Rx with warfarin, clopidogrel, mtx • Vascular surgery High-risk surgery (large fluid shifts; known cardiac risk >5%) • Esophageal • Liver • Pancreatic Intermediate-risk (cardiac risk 1-5%) • Head & neck • Intraperitoneal • Intrathoracic • Major ortho • Prostate

  29. Primary endpoint • Postoperative myocardial damage (TnT) • Secondary endpoints (any with first 30 days postop): • MACE • acute MI • cardiac arrest • severe arrhythmia • CV death • Cardio-cerebrovascular complications • MACE or stroke/TIA • Perioperative blood loss and major bleeding

  30. Aspirin use: • Absolute risk reduction = 7.2% [95% CI 1.3–13%] • NNT = 14 [95% CI 7.6–78] • Majority of patients having MACE had it early postop. • 1 in aspirin group and 8 in the placebo group had MACE within: • 1st 3 postop days • (P=0.02). • Patients on chronic aspirin rx pre-study (n=196; 90% of the study population): • MACE+: 10 in placebo vs 1 receiving aspirin • (P=0.03).

  31. What about increased EBL?!

  32. Prospective blinded placebo-control • To evaluate risk of recurrent bleeding with low-dose aspirin in pts with actively bleeding peptic ulcers (PU). • Eligible: • active PU bleed & cont. need for aspirin.

  33. Ann Intern Med. 2010;152(1):1-9

  34. 41 studies - 49,590 patients (14,981 on aspirin) • 12 retrospective obs., 19 prospective obs., 10 randomized • Dental, biopsies, multi-level spine, THA, major vascular/CEA, ENT, neurosurg, and TURP’s. • No change in bleeding complications, except: • TURP/Prostate procedures • aspirin users: 0.4–5.0 units of red blood cells, VS control patients 0.3–1.7 units

  35. Randomized double blind placebo-controlled • 220 high-risk CAD patients • Undergoing intermediate- to high- risk noncardiac surgery. • Randomized to: • daily low-dose aspirin or placebo

  36. Dermatologic Chu et al, J Am Acad Dermatol 2011 Alcalay et al, Dermatol Surg 2004 • Reviewed bleeding complications: biopsies, excisions, and Mohs procedures while on aspirin • No significant events; do not stop aspirin Cook-Norris et al, J Am Acad Dermatol 2011 • Retrospective analysis, 220 patients, 363 procedures on DUAL anti-platelet rx (aspirin + clopidogrel) • There were significant wound-related complications • none life-threatening • Attributed majority of problems to combination or the clopidogrel

  37. Vascular Rosenbaum et al, Ann Vasc Surg 2010 • Retrospective review of various antiplatelet regimes in CEA • 260 patients, 171 continued aspirin perioperatively • Neck hematoma – no difference • Other bleeding complications – no difference Burdess et al, Ann Surg 2010 • Prospective; lower extremity vascular • All on aspirin ± clopidogrel • No statistical difference in major or minor bleeding on dual APA • Aspirin alone did not impact bleeding-related issues

  38. Vascular - Lindblad et al, Stroke 1993 • Vascular surgeons blinded to aspirin use in CEA: • Could not differentiate patients on aspirin from patients off aspirin just from bleeding behavior

  39. Urologic - Renal transplantation Eng et al, Clin Transplant 2011 • Retrospective • 59 on aspirin preop vs 213 no anti-platelet agent • No significant differences in: • Transfusion requirements • Change in hemoglobin • Hospital LOS

  40. Urologic – Prostate Surgery - 1 • Aspirin may cause significant bleeding complications in TURP procedures. • vascular bed • endogenous urokinase • 2 studies from 1990’s: • Increased bleeding and need for significant more blood products in TURP patients on aspirin. • Wierod et al, Scand J Urol Nephrol 1998 • Thurston et al, Br J Urol 1993

  41. Urologic – Prostate Surgery - 2 Ala-Opas et al, Scand J Urol Nephrol 1996 • Chronic - 250mg/day • TURP • No greater EBL than nonusers • aspirin users: 358 mL vs nonusers: 478 mL

  42. Urologic – Prostate Surgery - 3 Nielsen et al, Scand J Urol Nephrol 2000 • Prospective, randomized, double-blind, placebo-controlled. • 150 mg continued perioperatively. • Intraop blood loss: • no difference • Postop blood loss: • aspirin group (n=26) significantly higher vs placebo (n=27) • median 284ml vs median 144ml, P=0.011 • No significant differences in: • Foley catheter removal • LOS • Transfusion requirements • Their group recommended holding aspirin for 10 days preoperatively.

More Related